Schedule of Investments (unaudited) April 30, 2021 | BlackRock Future Health ETF (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Common Stocks |
| |||||||
Biotechnology — 34.2% |
| |||||||
Acceleron Pharma Inc.(a) | 768 | $ | 95,977 | |||||
Agios Pharmaceuticals Inc.(a) | 1,079 | 60,208 | ||||||
Akeso Inc.(a)(b) | 6,000 | 41,136 | ||||||
Akouos Inc.(a) | 684 | 9,726 | ||||||
Alexion Pharmaceuticals Inc.(a) | 412 | 69,496 | ||||||
Allakos Inc.(a) | 548 | 59,798 | ||||||
Alnylam Pharmaceuticals Inc.(a) | 678 | 95,354 | ||||||
ALX Oncology Holdings Inc.(a) | 158 | 9,900 | ||||||
Annexon Inc.(a) | 448 | 8,929 | ||||||
Apellis Pharmaceuticals Inc.(a) | 416 | 21,079 | ||||||
Applied Molecular Transport Inc.(a)(c) | 405 | 23,283 | ||||||
Arcutis Biotherapeutics Inc.(a) | 1,048 | 35,108 | ||||||
Arena Pharmaceuticals Inc.(a) | 287 | 19,697 | ||||||
Argenx SE, ADR(a)(c) | 295 | 84,579 | ||||||
Arrowhead Pharmaceuticals Inc.(a) | 209 | 15,207 | ||||||
Avidity Biosciences Inc.(a) | 899 | 21,073 | ||||||
Beam Therapeutics Inc.(a) | 79 | 6,478 | ||||||
BioAtla Inc.(a)(c) | 318 | 15,770 | ||||||
Biohaven Pharmaceutical Holding Co. Ltd.(a) | 178 | 13,368 | ||||||
BioMarin Pharmaceutical Inc.(a) | 492 | 38,337 | ||||||
Biomea Fusion Inc.(a) | 1,153 | 19,543 | ||||||
Blueprint Medicines Corp.(a) | 186 | 17,916 | ||||||
Bridgebio Pharma Inc.(a) | 547 | 30,588 | ||||||
C4 Therapeutics Inc.(a) | 834 | 27,605 | ||||||
CareDx Inc.(a) | 556 | 43,963 | ||||||
ChemoCentryx Inc.(a) | 186 | 8,989 | ||||||
Connect Biopharma Holdings Ltd.(a) | 159 | 2,587 | ||||||
Cytokinetics Inc.(a) | 632 | 16,078 | ||||||
Decibel Therapeutics Inc.(a) | 353 | 3,219 | ||||||
Deciphera Pharmaceuticals Inc.(a) | 201 | 9,320 | ||||||
Design Therapeutics Inc.(a) | 179 | 4,695 | ||||||
Dicerna Pharmaceuticals Inc.(a) | 983 | 30,660 | ||||||
Enanta Pharmaceuticals Inc.(a) | 183 | 9,285 | ||||||
Fate Therapeutics Inc.(a) | 120 | 10,487 | ||||||
Forma Therapeutics Holdings Inc.(a) | 1,328 | 35,790 | ||||||
Galecto Inc.(a) | 1,091 | 6,241 | ||||||
Genetron Holdings Ltd.(a)(c) | 2,381 | 50,382 | ||||||
Genmab A/S(a) | 534 | 196,220 | ||||||
Genmab A/S, ADR(a)(c) | 1,688 | 62,237 | ||||||
Global Blood Therapeutics Inc.(a) | 834 | 34,010 | ||||||
Gracell Biotechnologies Inc.(a) | 1,889 | 23,008 | ||||||
Gritstone Oncology Inc.(a) | 697 | 6,308 | ||||||
Horizon Therapeutics PLC(a) | 513 | 48,540 | ||||||
Ideaya Biosciences Inc.(a) | 511 | 10,501 | ||||||
Immunocore Holdings PLC(a) | 136 | 5,489 | ||||||
Intellia Therapeutics Inc.(a) | 281 | 21,572 | ||||||
Iovance Biotherapeutics Inc.(a) | 1,052 | 33,075 | ||||||
Kadmon Holdings Inc.(a) | 5,522 | 22,419 | ||||||
Karyopharm Therapeutics Inc.(a) | 993 | 9,275 | ||||||
Keros Therapeutics Inc.(a) | 518 | 30,458 | ||||||
Kinnate Biopharma Inc.(a)(c) | 633 | 16,977 | ||||||
Kodiak Sciences Inc.(a) | 439 | 53,049 | ||||||
Krystal Biotech Inc.(a) | 250 | 19,860 | ||||||
Kymera Therapeutics Inc.(a) | 664 | 30,245 | ||||||
MacroGenics Inc.(a) | 209 | 6,763 | ||||||
Mersana Therapeutics Inc.(a) | 3,829 | 60,996 | ||||||
Mirati Therapeutics Inc.(a) | 222 | 36,901 | ||||||
Molecular Templates Inc.(a) | 444 | 4,156 |
Security | Shares | Value | ||||||
Biotechnology (continued) | ||||||||
Morphic Holding Inc.(a) | 217 | $ | 12,022 | |||||
Nkarta Inc.(a) | 312 | 9,937 | ||||||
Olema Pharmaceuticals Inc.(a) | 621 | 17,419 | ||||||
ORIC Pharmaceuticals Inc.(a) | 481 | 11,607 | ||||||
PMV Pharmaceuticals Inc.(a) | 1,185 | 39,970 | ||||||
Praxis Precision Medicines Inc.(a)(c) | 937 | 28,728 | ||||||
Prometheus Biosciences Inc.(a) | 693 | 17,027 | ||||||
Prothena Corp. PLC(a) | 889 | 23,594 | ||||||
PTC Therapeutics Inc.(a) | 533 | 21,965 | ||||||
RAPT Therapeutics Inc.(a) | 461 | 10,114 | ||||||
Relay Therapeutics Inc.(a) | 135 | 4,281 | ||||||
Rubius Therapeutics Inc.(a) | 360 | 9,007 | ||||||
Sage Therapeutics Inc.(a) | 145 | 11,420 | ||||||
Sarepta Therapeutics Inc.(a) | 178 | 12,610 | ||||||
Seagen Inc.(a) | 1,220 | 175,387 | ||||||
Seres Therapeutics Inc.(a) | 775 | 16,128 | ||||||
Sigilon Therapeutics Inc.(a) | 792 | 11,009 | ||||||
Taysha Gene Therapies Inc.(a) | 437 | 11,279 | ||||||
TCR2 Therapeutics Inc.(a) | 559 | 12,695 | ||||||
Translate Bio Inc.(a) | 805 | 18,692 | ||||||
United Therapeutics Corp.(a) | 146 | 29,428 | ||||||
Zai Lab Ltd., ADR(a) | 474 | 78,784 | ||||||
Zentalis Pharmaceuticals Inc.(a) | 556 | 32,982 | ||||||
Zymeworks Inc.(a) | 617 | 20,065 | ||||||
|
| |||||||
2,440,060 | ||||||||
Diversified Financial Services — 1.2% | ||||||||
Eucrates Biomedical Acquisition Corp.(a) | 1,857 | 18,384 | ||||||
Health Assurance Acquisition Corp., Class A(a) | 2,816 | 28,921 | ||||||
Helix Acquisition Corp., Class A(a) | 445 | 4,499 | ||||||
Lifesci Acquisition II Corp.(a) | 1,515 | 15,226 | ||||||
MedTech Acquisition Corp./NY, Class A(a) | 1,908 | 18,660 | ||||||
|
| |||||||
85,690 | ||||||||
Electronic Equipment, Instruments & Components — 0.5% |
| |||||||
908 Devices Inc.(a) | 632 | 33,490 | ||||||
|
| |||||||
Health Care Equipment & Supplies — 30.5% | ||||||||
ABIOMED Inc.(a) | 197 | 63,184 | ||||||
Alcon Inc.(a) | 1,906 | 143,770 | ||||||
Cardiovascular Systems Inc.(a) | 412 | 16,612 | ||||||
ConvaTec Group PLC(b) | 11,456 | 34,610 | ||||||
Demant A/S(a) | 1,713 | 86,015 | ||||||
DENTSPLY SIRONA Inc. | 1,297 | 87,560 | ||||||
DexCom Inc.(a)(c) | 126 | 48,649 | ||||||
Eargo Inc.(a) | 417 | 23,869 | ||||||
Edwards Lifesciences Corp.(a) | 687 | 65,622 | ||||||
Envista Holdings Corp.(a) | 954 | 41,289 | ||||||
GN Store Nord A/S | 1,544 | 139,563 | ||||||
Hill-Rom Holdings Inc. | 357 | 39,349 | ||||||
Insulet Corp.(a)(c) | 349 | 103,032 | ||||||
Intuitive Surgical Inc.(a) | 181 | 156,565 | ||||||
Masimo Corp.(a) | 422 | 98,187 | ||||||
Nevro Corp.(a) | 612 | 105,760 | ||||||
Novocure Ltd.(a) | 54 | 11,021 | ||||||
NuVasive Inc.(a) | 335 | 23,936 | ||||||
Penumbra Inc.(a) | 133 | 40,697 | ||||||
Pulmonx Corp.(a) | 239 | 11,235 | ||||||
ResMed Inc. | 444 | 83,459 | ||||||
Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Class A | 600 | 43,258 | ||||||
SI-BONE Inc.(a) | 341 | 12,105 | ||||||
Silk Road Medical Inc.(a) | 737 | 45,060 |
| 1 |
Schedule of Investments (unaudited) (continued) April 30, 2021 | BlackRock Future Health ETF (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Health Care Equipment & Supplies (continued) | ||||||||
SmileDirectClub Inc.(a) | 2,918 | $ | 31,033 | |||||
Sonova Holding AG, Registered(a) | 177 | 52,418 | ||||||
STERIS PLC | 339 | 71,536 | ||||||
Straumann Holding AG, Registered | 83 | 118,714 | ||||||
Tandem Diabetes Care Inc.(a) | 337 | 30,970 | ||||||
Teleflex Inc. | 353 | 149,135 | ||||||
Zimmer Biomet Holdings Inc. | 1,094 | 193,813 | ||||||
|
| |||||||
2,172,026 | ||||||||
Health Care Providers & Services — 11.7% | ||||||||
Addus HomeCare Corp.(a) | 109 | 11,532 | ||||||
agilon health Inc.(a) | 618 | 19,486 | ||||||
Alignment Healthcare Inc.(a) | 760 | 20,170 | ||||||
Amedisys Inc.(a) | 565 | 152,465 | ||||||
Amplifon SpA(a) | 1,580 | 66,817 | ||||||
Centene Corp.(a) | 940 | 58,036 | ||||||
Chemed Corp. | 60 | 28,597 | ||||||
Encompass Health Corp. | 1,015 | 86,133 | ||||||
Guardant Health Inc.(a) | 126 | 20,031 | ||||||
Humana Inc. | 200 | 89,048 | ||||||
Innovage Holding Corp.(a) | 182 | 4,634 | ||||||
Jinxin Fertility Group Ltd.(b) | 50,000 | 128,752 | ||||||
LHC Group Inc.(a) | 607 | 126,420 | ||||||
Rede D’Or Sao Luiz SA(b) | 1,896 | 25,127 | ||||||
|
| |||||||
837,248 | ||||||||
Health Care Technology — 1.8% | ||||||||
Certara Inc.(a)(c) | 1,123 | 35,723 | ||||||
Privia Health Group Inc.(a) | 290 | 10,533 | ||||||
Teladoc Health Inc.(a) | 478 | 82,383 | ||||||
|
| |||||||
128,639 | ||||||||
Life Sciences Tools & Services — 10.8% | ||||||||
Avantor Inc.(a) | 1,875 | 60,075 | ||||||
Berkeley Lights Inc.(a) | 830 | 40,762 | ||||||
Bruker Corp. | 475 | 32,547 | ||||||
Charles River Laboratories International Inc.(a) | 222 | 73,804 | ||||||
Gerresheimer AG | 381 | 41,026 | ||||||
Illumina Inc.(a) | 86 | 33,784 | ||||||
IQVIA Holdings Inc.(a) | 354 | 83,080 | ||||||
Joinn Laboratories China Co. Ltd., Class H(a) | 600 | 10,815 | ||||||
Lonza Group AG, Registered | 87 | 55,402 | ||||||
Olink Holding AB(a) | 63 | 2,218 | ||||||
Sotera Health Co.(a) | 2,721 | 70,093 | ||||||
WuXi AppTec Co. Ltd., Class H(b) | 6,200 | 146,641 | ||||||
Wuxi Biologics Cayman Inc., New(a)(b) | 8,500 | 119,836 | ||||||
|
| |||||||
770,083 | ||||||||
Pharmaceuticals — 5.7% | ||||||||
Astellas Pharma Inc. | 2,500 | 37,521 | ||||||
Eisai Co. Ltd. | 500 | 32,611 |
Security | Shares | Value | ||||||
Pharmaceuticals (continued) | ||||||||
Hansoh Pharmaceutical Group Co. Ltd.(a)(b) | 24,000 | $ | 103,671 | |||||
Marinus Pharmaceuticals Inc.(a) | 1,154 | 16,975 | ||||||
Merck KGaA | 491 | 86,384 | ||||||
Nektar Therapeutics(a) | 868 | 17,021 | ||||||
Relmada Therapeutics Inc.(a) | 642 | 24,756 | ||||||
UCB SA | 954 | 88,498 | ||||||
|
| |||||||
407,437 | ||||||||
|
| |||||||
Total Common Stocks — 96.4% | 6,874,673 | |||||||
|
| |||||||
Warrants | ||||||||
Diversified Financial Services — 0.0% | ||||||||
Eucrates Biomedical Acquisition Corp., | 619 | 712 | ||||||
MedTech Acquisition Corp./NY, | 636 | 585 | ||||||
|
| |||||||
1,297 | ||||||||
Health Care Technology — 0.0% | ||||||||
Health Assurance Acquisition Corp., | 704 | 1,626 | ||||||
|
| |||||||
Total Warrants — 0.0% | 2,923 | |||||||
|
| |||||||
Short-Term Investments | ||||||||
Money Market Funds — 7.0% | ||||||||
BlackRock Cash Funds: Institutional, | 306,356 | 306,510 | ||||||
BlackRock Cash Funds: Treasury, | 190,000 | 190,000 | ||||||
|
| |||||||
496,510 | ||||||||
|
| |||||||
Total Short-Term Investments — 7.0% | 496,510 | |||||||
|
| |||||||
Total Investments in Securities — 103.4% | 7,374,106 | |||||||
Other Assets, Less Liabilities — (3.4)% | (241,929 | ) | ||||||
|
| |||||||
Net Assets — 100.0% | $ | 7,132,177 | ||||||
|
|
(a) | Non-income producing security. |
(b) | Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors. |
(c) | All or a portion of this security is on loan. |
(d) | Affiliate of the Fund. |
(e) | Annualized 7-day yield as of period-end. |
(f) | All or a portion of this security was purchased with cash collateral received from loaned securities. |
2 |
|
Schedule of Investments (unaudited) (continued) April 30, 2021 | BlackRock Future Health ETF |
Affiliates
Investments in issuers considered to be affiliate(s) of the Fund during the period ended April 30, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
Affiliated Issuer | Value at 09/29/20(a) | Purchases at Cost | Proceeds from Sales | Net Realized Gain (Loss) | Change in Unrealized Appreciation (Depreciation) | Value at 04/30/21 | Shares Held at 04/30/21 | Income | Capital Gain | |||||||||||||||||||||||||||
BlackRock Cash Funds: Institutional, SL Agency Shares | $ | — | $ | 306,522 | (b) | $ | — | $ | (9 | ) | $ | (3 | ) | $ | 306,510 | 306,356 | $ | 322 | (c) | $ | — | |||||||||||||||
BlackRock Cash Funds: Treasury, SL Agency Shares | — | 190,000 | (b) | — | — | — | 190,000 | 190,000 | 40 | — | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||||||
$ | (9 | ) | $ | (3 | ) | $ | 496,510 | $ | 362 | $ | — | |||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
(a) | The Fund commenced operations on September 29, 2020. |
(b) | Represents net amount purchased (sold). |
(c) | All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
Fair Value Measurements
Various inputs are used in determining the fair value of financial instruments. For description of the input levels and information about the Fund’s policy regarding valuation of financial instruments, refer to a recently published shareholder report. Shareholder reports are available on the Fund’s website at iShares.com and on the U.S. Securities and Exchange Commission website at sec.gov.
The following table summarizes the value of the Fund’s investments according to the fair value hierarchy as of April 30, 2021. The breakdown of the Fund’s investments into major categories is disclosed in the Schedule of Investments above.
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Investments | ||||||||||||||||
Assets | ||||||||||||||||
Common Stocks | $ | 6,874,673 | $ | — | $ | — | $ | 6,874,673 | ||||||||
Warrants | 2,923 | — | — | 2,923 | ||||||||||||
Money Market Funds | 496,510 | — | — | 496,510 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
$ | 7,374,106 | $ | — | $ | — | $ | 7,374,106 | |||||||||
|
|
|
|
|
|
|
|
Portfolio Abbreviations - Equity
ADR American Depositary Receipt
| 3 |